Role of Cysteinyl Leukotrienes in the Pathogenesis of Asthma in Obesity

Completed

Conditions studied: Asthma, Obesity

In brief

The purpose of this study is to examine whether there are higher levels of cysteinyl leukotrienes in obese subjects than in non-obese subjects. Cysteinyl leukotrienes are pro-inflammatory substances that cause asthma by narrowing the airways of the lung. The investigators want to see if subjects with increased fat stores and therefore increased leptin, which is a fat-related protein that regulates leukotrienes, have increased levels of leukotrienes in the blood, lung and urine. The investigators would also like to determine the relationship between cysteinyl leukotrienes and exhaled nitric oxide levels in asthmatics with and without obesity. Nitric oxide is anti-inflammatory and suppresses leukotriene synthesis.

Key facts

Study ID

NCT01158573

Run by

University of Michigan

People needed

117

Starts

2010-07-01

Expected to finish

2013-05-01

Last updated by the study team

2018-01-24

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 18-65 yr old adults with asthma, non-smoking for at least one year
• Healthy non-smoking adults, aged 18-65 without asthma
• Heavy subjects with BMI > 30 kg/m2
• Subjects with normal weight (BMI between 20-25 kg/m2)
• Subject not taking anti-leukotriene therapy (Singulair, Accolate, Zyflo)

You may not qualify if…

• No chronic oral steroid use
• No recent history of infection
• No recent history of flare of lung disease

Where it is running

• University of Michigan — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.